

Cindy Kesty¹, Nuswil Bernolian¹, Putri Mirani¹, Theodorus², Phey Liana³, Abarham Martadiansyah¹, Peby Maulina Lestari¹

¹Department of Obstetrics and Gynecology ² Department of Pharmacology ³ Department of Clinical Pathology. Faculty of Medicine Universitas Sriwijaya, dr. Mohammad Hoesin General Hospital, Palembang, South Sumatera, Indonesia

Correspondence: cindy.kesty@iddo.org

INTRODUCTION

VULVOVAGINITIS → inflammatory & infectious disease of the vulva and vagina → vaginal discharge, odor, itching, & burning

Andini RK et al (2019): 79.4% vs 20.6% with vs without pathologic fluor albus

40–50% BV, 20–25% VVC, & 15–20% trichomoniasis

Impact on **MOTHER & FETUS**

What is the therapy? → Empiric therapy or Current therapy?

OBJECTIVE

To compare the efficacy between **dequalinium chloride (DC)** & **metronidazole + nystatin (MN)** as a treatment for vulvovaginitis (BV, VVC, trichomoniasis) in pregnancy

METHODS

- **RCT**, open-label at Dept of Obgyn RSMH Palembang from May 2021 - March 2022.
- 83 samples → 13 samples were dropped out → **70 pregnant women with vulvovaginitis** & were divided into 2 groups (DC & MN).
- Vaginal swab was examined twice on the 1st day → Gram examination, culture, resistance, colony counting & 7th day → Gram examination & culture.

CONCLUSION

- Most of vulvovaginitis in pregnant women was bacterial vaginosis (*Gardnerella vaginalis*), candidiasis (*Candida albicans*), and other bacterial infection (positive Gram bacteria: *Staphylococcus hemolyticus* and negative Gram bacteria: *Escherichia coli*).
- Dequalinium chloride & metronidazole + nystatin are **equally effective** against vulvovaginitis in pregnancy

REFERENCES

- Paladine HL, Desai UA. Vaginitis: Diagnosis and treatment. Am Fam Physician. 2018;97(5):321-9.
- Amabebe E, Anumba DOC. The vaginal microenvironment: The physiologic role of lactobacilli. Front Med. 2018;5:1-11.
- Godha K, Tucker KM, Biehler C, Archer DF, Mirkin S. Human vaginal pH and microbiota: An update. Gynecol Endocrinol. 2018;34(6):451-5.
- Konadu DG, Owusu-Ofori A, Yidana Z, Boadu F, Iddrisu LF, Adu-Gyasi D, et al. Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. BMC Pregnancy Childbirth. 2019;19(1):1-10.
- Waikhom SD, Afeke I, Kwawu GS, Mbroh HK, Osei GY, Louis B, et al. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: Species identification and antifungal susceptibility of Candida isolates. BMC Pregnancy Childbirth. 2020;20(1):1-14.
- Chooprasertsuk W, Somboonporn W, Soontrapa S, Salang LL, Amnatbuddee S. Combined vaginal administration of nystatin, diiodohydroxyquin, and benzalkonium chloride versus oral metronidazole for the treatment of bacterial vaginosis. Int J Gynecol Obstet. 2019;145(3):261-7.

RESULT

Clinical Characteristics of Study Subjects

Variables	Groups		p value
	DC (n = 35)	MN (n = 35)	
Bacterial vaginosis, n (%)			
• Positive	20 (57.1)	13 (37.1)	0.151 ^a
• Negative	15 (42.9)	22 (62.9)	
Trichomoniasis, n (%)			
• Positive	0 (0)	0 (0)	-
• Negative	35 (100)	35 (100)	
Candidiasis, n (%)			
• Positive	10 (28.6)	13 (37.1)	0.611 ^a
• Negative	25 (71.4)	22 (62.9)	
Nugent score			
• Mean ± SD	5.600 ± 2.488	5.314 ± 2.541	0.516 ^b
• Median (min-max)	7 (0–8)	6 (0–9)	
Colony counting			
• Mean ± SD	9,061 ± 37,330	15,172 ± 54,998	0.456 ^b
• Median (min-max)	0 (0–200.000)	0 (0–300.000)	


^aChi Square Test, *p < 0.05 ^bMann Whitney, *p < 0.05

Comparison of Recovery between the Two Treatment Groups


Variables	Groups		p value
	DC (n = 35)	MN (n = 35)	
Recovery, n (%)			
• Yes	28 (80.0)	27 (77.1)	1.000
• No	7 (20.0)	8 (22.9)	

Chi-square test, *p < 0.05


Nugent Score



Colony Count



Antifungal Sensitivity and Resistance



Antibiotic Sensitivity and Resistance

